D
Di Zhang
Researcher at University of Pittsburgh
Publications - 8
Citations - 893
Di Zhang is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: KRAS & Minimal clinically important difference. The author has an hindex of 7, co-authored 8 publications receiving 644 citations.
Papers
More filters
Journal ArticleDOI
Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis.
Dio Kavalieratos,Jennifer Corbelli,Di Zhang,J. Nicholas Dionne-Odom,Natalie C. Ernecoff,Janel Hanmer,Zachariah Hoydich,Dara Z. Ikejiani,Michele Klein-Fedyshin,Camilla Zimmermann,Sally C. Morton,Robert M. Arnold,Lucas Heller,Yael Schenker +13 more
TL;DR: Palliative care was associated consistently with improvements in advance care planning, patient and caregiver satisfaction, and lower health care utilization, and evidence of associations with other outcomes was mixed.
Journal ArticleDOI
Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study.
TL;DR: For T1aN0M0 RCC, TA confers cancer-specific survival and OS similar to those seen with surgical management, with significantly fewer adverse outcomes at 1 year after the procedure and similar rates of secondary cancer events compared with surgery.
Journal ArticleDOI
KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
TL;DR: Patients with CRC and KRAS wt may derive greater survival benefit from (90)Y radioembolization therapy than patients with KRAS mutant, andMultivariate Cox regression analysis demonstrated Child-Pugh class, CEA, and KRas status to be independent prognostic factors for OS, even when correcting for the effect of chemotherapy after (90).
Journal ArticleDOI
Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90 Y-radioembolization for hepatocellular carcinoma
TL;DR: This meta-analysis shows greater 1-year survival benefit for DEB-TACE over 90Y-radioembolization, which has a favourable 2- & 3- year survival benefit trend over90Y- RadioEmbolization.
Journal ArticleDOI
Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90
Michael J. Magnetta,Anish Ghodadra,Steven J. Lahti,Minzhi Xing,Di Zhang,Hyun Soo Kim,Hyun Soo Kim +6 more
TL;DR: Longer PFS is associated with KRAS wt vs. mut following SIRT Y90, and only KRas wt was an independent prognostic factor for longer PFS in multivariate analysis.